Cardiac effects of myoregulin in ischemia-reperfusion

• Published in: Peptides (New York, N.Y. : 1980) Vol. 174; p. 171156
• Main Authors: Appleby, Sarah, Aitken-Buck, Hamish M., Holdaway, Mark S., Byers, Mathew S., Frampton, Chris M., Paton, Louise N., Richards, A. Mark, Lamberts, Regis R., Pemberton, Christopher J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2024
• Subjects: Gene expression; Hemodynamics; Ischemia/reperfusion; Langendorff isolated rat heart; Myoregulin; SERCA; Myoregulin; Hemodynamics; Gene expression; SERCA; Ischemia/reperfusion; Langendorff isolated rat heart
• ISSN: 0196-9781; 1873-5169
• DOI: 10.1016/j.peptides.2024.171156

Myoregulin is a recently discovered micropeptide that controls calcium levels by inhibiting the intracellular calcium pump sarco-endoplasmic reticulum Ca2+-ATPase (SERCA). Keeping calcium levels balanced in the heart is essential for normal heart functioning, thus myoregulin has the potential to be a crucial regulator of cardiac muscle performance by reducing the rate of intracellular Ca2+ uptake. We provide the first report of myoregulin mRNA expression in human heart tissue, absence of expression in human plasma, and the effects of myoregulin on cardiac hemodynamics in an ex vivo Langendorff isolated rat heart model of ischemia/reperfusion. In this preliminary study, myoregulin provided a cardio-protective effect, as assessed by preservation of left ventricular contractility and relaxation, during ischemia/reperfusion. This study provides the foundation for future research in this area. •Myoregulin mRNA is expressed in human heart tissue.•Myoregulin only influenced heart function during ischaemia/reperfusion injury.•Myoregulin had a protective effect on left ventricular contractility and relaxation.